A phase I dose-escalation study of NK012 administered intravenously as a single dose every three weeks in patients with refractory solid tumors

Trial Profile

A phase I dose-escalation study of NK012 administered intravenously as a single dose every three weeks in patients with refractory solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2016

At a glance

  • Drugs NK 012 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Nippon Kayaku
  • Most Recent Events

    • 23 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top